Abstract
Objective: The influence of intrauterine and perinatal infections on fetal and neonatal mortality rates and childhood morbidity is substantial. Toxoplasmosis gondii, cytomegalovirus (CMV), and rubella are widely recognized as the major causative agents of in utero infection. The surveillance of preventable and treatable diseases within populations at risk are crucial for public health. The objective of this study is to investigate the seropositivity rates and avidity incidences of T. gondii, CMV, and rubella in pregnant women during the first trimester.
Methods: The electrochemiluminescence immunoassay method (Elecsys, Roche, Germany) was employed for the detection of the anti-Toxo IgM, anti-Toxo IgG, anti-CMV IgM, anti-CMV IgG, anti-rubella IgM, and anti-rubella IgG during the time period of January 1, 2021, to June 15, 2023. The anti-Toxo IgG, anti-CMV, and anti-rubella IgG avidity tests were performed with the enzyme-linked fluorescent assay method (VIDAS, bioMérieux, France).
Results: The T. gondii IgM incidance was 2.1%; and the T. gondii IgG seroprevalance was 22%. For T. gondii, low avidity was observed in 13.6% (n = 31) of cases, while high avidity index was detected in 75.8% (n = 172) of cases. The anti-CMV IgM incidance was 1.6%; while IgG seroprevalance was 96.9%. The IgG avidity with a high index for CMV was determined as 99.4%. The anti-rubella IgM incidance was 0.8%; while the IgG seroprevalance was found to be 98.7%. The IgG avidity with a high index for Rubella was 99.1%.
Conclusion: Seroprevalance of T.gondii, CMV, and rubella may vary according to geographical and socioeconomic conditions. Treatment for T. gondii diagnosed during pregnancy, preventive behavioral measures for CMV and vaccination against rubella prior to pregnancy may help reduce congenital infections. The prioritization of T. gondii, CMV, and rubella screening in high-risk populations, including women of reproductive age and pregnant women, is crucial for public health.
Publisher
Journal of Biotechnology and Strategic Health Research
Reference60 articles.
1. 1. Ostrander B, Bale JF. Congenital and perinatal infections. Handb Clin Neurol 2019; 162: 133-153. doi: 10.1016/B978-0-444-64029-1.00006-0.
2. 2. Melchor SJ, Ewald SE. Disease Tolerance in Toxoplasma Infection. Front Cell Infect Microbiol 2019; 9: 185.
3. 3. Cook AJ, Gilbert RE, Buffolano W, et al. Sources of toxoplasma infection in pregnant women: European multicentre case-control study. European Research Network on Congenital Toxoplasmosis. BMJ. 2000;321(7254):142-147. doi:10.1136/bmj.321.7254.142.
4. 4. Montoya JG, Kovacs JA, Remington JS. Toxoplasma gondii. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 6th ed. Philadelphia: Elsevier Churchill Livingstone, 2005:3170-198.
5. 5. Robert-Gangneux F, Murat JB, Fricker-Hidalgo H, et al. The placenta: a main role in congenital toxoplasmosis? Trends Parasitol 2011; 27 :530.